Trial · NCT07886398
Sleep MAPP in the Polytrauma/TBI System of Care
NCT07886398, Not applicable, Not yet recruiting, VA Office of Research and Development
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Sleep MAPP in the Polytrauma/TBI System of Care. Trials, record NCT07886398. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07886398
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Sleep MAPP in the Polytrauma/TBI System of Care
- NCT number
- NCT07886398
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 900 participants, estimated
- Lead sponsor
- VA Office of Research and Development
- Conditions
- Insomnia Disorder, Mild Traumatic Brain Injury
- Interventions
- Sleep MAPP Care Pathway
- First posted
- 2026-10-21
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes40
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Provider-rated feasibility of Sleep MAPP decision support tool | End of the 12-month implementation phase | Provider respondents complete the four-item Feasibility of Intervention Measure for the Sleep MAPP decision-support tool. The outcome is the percentage of respondents with a mean item score of 4.0 (agree) or higher. Higher percentages indicate greater perceived feasibility. |
| Primary | Provider-rated feasibility of insomnia screening with the Insomnia Severity Index | End of the 12-month implementation phase | Provider respondents complete the Feasibility of Intervention Measure for Insomnia Severity Index screening. The outcome is the percentage of respondents with a mean item score of 4.0 (agree) or higher. Higher percentages indicate greater perceived feasibility. |
| Primary | Provider-rated feasibility of Brief Behavioral Therapy for Insomnia (BBTI) training | End of the 12-month implementation phase | Provider respondents complete the Feasibility of Intervention Measure for Brief Behavioral Therapy for Insomnia training. The outcome is the percentage of respondents with a mean item score of 4.0 (agree) or higher. Higher percentages indicate greater perceived feasibility. |
| Primary | Provider-rated feasibility of Brief Behavioral Therapy for Insomnia (BBTI) | End of the 12-month implementation phase | Provider respondents complete the Feasibility of Intervention Measure for delivery of Brief Behavioral Therapy for Insomnia in routine care. The outcome is the percentage of respondents with a mean item score of 4.0 (agree) or higher. Higher percentages indicate greater perceived feasibility. |
| Primary | Provider-rated acceptability of the Sleep MAPP decision-support tool | End of the 12-month implementation phase | Provider respondents complete the Acceptability of Intervention Measure for the Sleep MAPP decision-support tool. The outcome is the percentage of respondents with a mean item score of 4.0 (agree) or higher. Higher percentages indicate greater perceived acceptability. |
| Primary | Provider-rated acceptability of insomnia screening with the Insomnia Severity Index | End of the 12-month implementation phase | Provider respondents complete the Acceptability of Intervention Measure for Insomnia Severity Index screening. The outcome is the percentage of respondents with a mean item score of 4.0 (agree) or higher. Higher percentages indicate greater perceived acceptability. |
| Primary | Provider-rated acceptability of Brief Behavioral Therapy for Insomnia (BBTI) training | End of the 12-month implementation phase | Provider respondents complete the Acceptability of Intervention Measure for Brief Behavioral Therapy for Insomnia training. The outcome is the percentage of respondents with a mean item score of 4.0 (agree) or higher. Higher percentages indicate greater perceived acceptability. |
| Primary | Provider-rated acceptability of Brief Behavioral Therapy for Insomnia (BBTI) delivery | End of the 12-month implementation phase | Provider respondents complete the Acceptability of Intervention Measure for delivery of Brief Behavioral Therapy for Insomnia in routine care. The outcome is the percentage of respondents with a mean item score of 4.0 (agree) or higher. Higher percentages indicate greater perceived acceptability. |
| Primary | Veteran-rated acceptability of insomnia screening using the Insomnia Severity Index | Within approximately 1 month after final BBTI session; from the start of the 12-month implementation phase to the end of the 6-month post-implementation phase. | Veterans complete the 8-item Client Satisfaction Questionnaire (CSQ-8) to rate satisfaction with Insomnia Severity Index screening. Items are scored from 1 to 4 and summed to produce a total score ranging from 8 to 32, with higher scores indicating greater satisfaction. The outcome is the percentage of respondents with a mean item score of 3.0 or higher, equivalent to a total score of 24 or higher. |
| Primary | Veteran-rated acceptability of Brief Behavioral Therapy for Insomnia (BBTI) | Within approximately 1 month after final BBTI session; from the start of the 12-month implementation phase to the end of the 6-month post-implementation phase. | Veterans complete the 8-item Client Satisfaction Questionnaire (CSQ-8) to rate satisfaction with Brief Behavioral Therapy for Insomnia. Items are scored from 1 to 4 and summed to produce a total score ranging from 8 to 32, with higher scores indicating greater satisfaction. The outcome is the percentage of respondents with a mean item score of 3.0 or higher, equivalent to a total score of 24 or higher. |
1 to 10 of 40Source ClinicalTrials.gov
See all 40 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07886398
GET https://conductscience.org/api/trials/v1/NCT07886398/registered?page=2